secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2025-08-21T23:59:59+00:00
Accession:  0001140361-25-032176
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Ionis' DAWNZERA (donidalorsen) for HAE prophylaxis in patients 12+
-------------------------------------------------------------------------------

- First and only RNA-targeted HAE medicine; self-administered every 4 or 8 weeks via autoinjector.
- Phase 3 OASIS-HAE: Q4W reduced monthly attack rate 81% vs placebo (primary endpoint); 87% from second dose.
- OASISplus OLE: 94% attack rate reduction after one year; switch cohort reduced attacks 62% vs prior therapy.
- Ionis' second independent launch in nine months; 84% of patients surveyed preferred DAWNZERA over prior treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036125032176/0001140361-25-032176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036125032176/ef20054334_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-032176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer